{"name":"ASIS Corporation","slug":"asis-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Efficacy of Botox subdermally at Week 12","genericName":"Efficacy of Botox subdermally at Week 12","slug":"efficacy-of-botox-subdermally-at-week-12","indication":"Other","status":"phase_1"},{"name":"Efficacy of Botox subdermally at Week 18","genericName":"Efficacy of Botox subdermally at Week 18","slug":"efficacy-of-botox-subdermally-at-week-18","indication":"Other","status":"phase_1"},{"name":"Efficacy of Botox subdermally at Week 24","genericName":"Efficacy of Botox subdermally at Week 24","slug":"efficacy-of-botox-subdermally-at-week-24","indication":"Other","status":"phase_1"},{"name":"Efficacy of Botox subdermally at Week 30","genericName":"Efficacy of Botox subdermally at Week 30","slug":"efficacy-of-botox-subdermally-at-week-30","indication":"Other","status":"phase_1"},{"name":"Adverse Reactions of Botox intramuscularly","genericName":"Adverse Reactions of Botox intramuscularly","slug":"adverse-reactions-of-botox-intramuscularly","indication":"blepharospasm","status":"phase_1"},{"name":"Adverse Reactions of Gammagard subcutaneously at Week 12","genericName":"Adverse Reactions of Gammagard subcutaneously at Week 12","slug":"adverse-reactions-of-gammagard-subcutaneously-at-week-12","indication":"Other","status":"phase_1"},{"name":"Efficacy of Botox intramuscularly at Week 6","genericName":"Efficacy of Botox intramuscularly at Week 6","slug":"efficacy-of-botox-intramuscularly-at-week-6","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Adverse Reactions of Enbrel subcutaneously","genericName":"Adverse Reactions of Enbrel subcutaneously","slug":"adverse-reactions-of-enbrel-subcutaneously","indication":"Rheumatoid Arthritis","status":"phase_1"}]}],"pipeline":[{"name":"Efficacy of Botox subdermally at Week 12","genericName":"Efficacy of Botox subdermally at Week 12","slug":"efficacy-of-botox-subdermally-at-week-12","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Efficacy of Botox subdermally at Week 18","genericName":"Efficacy of Botox subdermally at Week 18","slug":"efficacy-of-botox-subdermally-at-week-18","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Efficacy of Botox subdermally at Week 24","genericName":"Efficacy of Botox subdermally at Week 24","slug":"efficacy-of-botox-subdermally-at-week-24","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Efficacy of Botox subdermally at Week 30","genericName":"Efficacy of Botox subdermally at Week 30","slug":"efficacy-of-botox-subdermally-at-week-30","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adverse Reactions of Botox intramuscularly","genericName":"Adverse Reactions of Botox intramuscularly","slug":"adverse-reactions-of-botox-intramuscularly","phase":"phase_1","mechanism":"Botulinum toxin inhibits acetylcholine release at neuromuscular junctions","indications":["blepharospasm","strabismus","cervical dystonia","hemicrania continua"],"catalyst":""},{"name":"Adverse Reactions of Enbrel subcutaneously","genericName":"Adverse Reactions of Enbrel subcutaneously","slug":"adverse-reactions-of-enbrel-subcutaneously","phase":"phase_1","mechanism":"Tumor necrosis factor-alpha inhibitor","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Plaque Psoriasis"],"catalyst":""},{"name":"Adverse Reactions of Gammagard subcutaneously at Week 12","genericName":"Adverse Reactions of Gammagard subcutaneously at Week 12","slug":"adverse-reactions-of-gammagard-subcutaneously-at-week-12","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Efficacy of Botox intramuscularly at Week 6","genericName":"Efficacy of Botox intramuscularly at Week 6","slug":"efficacy-of-botox-intramuscularly-at-week-6","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOcHRFdExLbmZxUTRrM18xZk9MMTgwWC15N2JxdlNQNEliSEdiX0pyUlNjeGd6VUc2djl2b2hEWXNCYUwwcFZBUXo0M1BDRHBnUXEwTTc4azNnelFiQUQ3emRUUVMwaTBxVGdPU3hZSjFEcW5rc1NYdS1TUmRJb2Q3clVZYXE0ZFRGRkhCSGxxRnBuOWZlcTRqcWVRQ3FNaFZPanBkTE9LTFNXaGZiWFR5clAyLUNIYTV6NUZvNWhURnNyN2dmRkRIaFVoUzJVQW84R2dPbmlacll5ZjJ5SnVyWDlEakRITmFE?oc=5","date":"2025-12-04","type":"pipeline","source":"ASIS","summary":"How Executive Protection is Changing One Year After UnitedHealthcare CEO Attack - ASIS","headline":"How Executive Protection is Changing One Year After UnitedHealthcare CEO Attack","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQcG9aNlV1Q3NGLU5jeGdkcVlacWlqZUh5WVZETFV1VkotakZLczdlV3VTTklRdTRVdFlTTTBqM3VnQkt3d09HQ1RGWm04VUROdm9JeG1sZkVlTVN1VGJYZktTbVpQU2R6bWwyN01PWUxQVXVqbjNySXV3M25GWTdPdGJnaXRYWE94YlRKYUhDRUFGVVNhYjhVbXZka3Y0NUk2c1ZqMlZxUDVBYmp1NGZhVEJUa0F6UQ?oc=5","date":"2025-11-01","type":"pipeline","source":"ASIS","summary":"Truth Under Siege: How Disinformation Threatens Corporate Security - ASIS","headline":"Truth Under Siege: How Disinformation Threatens Corporate Security","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxObkk5cVgtYmFlZzIzcWs5a1ljeE9ibTQ0LWVWM0J6dGFtQVh5NlBKc1hrNHJDbG9CTldkOEhyYlVVZUpUSFVmRG1adkFpLWRNRUxjaG5lMzNNdDZCTFFucDcwdU1CeWotR1MzNUw5OUx0UmczTExqR2FKc2pOazVfdEwtWnFYWVNaMl9WWUlwSG9wZWpnQ2Izcmh3?oc=5","date":"2024-12-19","type":"pipeline","source":"ASIS","summary":"The Kidnapping and Killing of Two Chinese Executives in the Philippines Spurs Heightened Travel Risk Concerns - ASIS","headline":"The Kidnapping and Killing of Two Chinese Executives in the Philippines Spurs Heightened Travel Risk Concerns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPeVU4Z05ZNV9zNUdVdzNEZDNFTHNkcUIwUDdxcXUwd3dhUFR5dGgwaWExVGpZb3RmckNEeHR6M3lGYVZ1ejJ0bXN4a2phZXNxOGpIbkliWXpJZy0xTi1sREZMbU8zTk1RcFNxZ2dDM1NpUlpWUWxaR3VLU1JSWTlWdjdGVXByajJ3RDVqdjJzaXdQbm1fVURDd1dzTzZSYjNzalRHSVoxME5BYnhLd3otZWVsQ00yaTJFQ0d0UVFiaDhaeWk1eUxCeHE3OHEwVHNCLTZobENzc2ZzUEY5bjlwTFFYcVN2REI2clVlSTFuOXUyOHdaYTlDdTFFR28?oc=5","date":"2022-11-16","type":"pipeline","source":"ASIS","summary":"Twitter Verification Changes Unleash Deluge of Impersonations, Misinformation, and Reputation Risks - ASIS","headline":"Twitter Verification Changes Unleash Deluge of Impersonations, Misinformation, and Reputation Risks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNeGRRcVRPZnljdWZqQjBzNGJtV2huZUJLT1BmbDgzUkNWNWRKay1oYUVWaVB6Z0oxSjU4Xy1EWWlNWmxoZ2Q2eEhhNDFDQlhfc2QxVTRKM3hZRi1FeV8zS2g4U0JCeE9kdm1EN0M5ZGZ1UzRGOUZPaTdjMmF0TnZQTTFoR1VMLXBJU1BZaFRJNXBQQmZ2Z1NqQzJsVTFDcUh5X0xjSDg3VHl0UTNtQzlNQ2JXRFNJOWxCZC1vbi1nRGg3RmxkOUZYS1Q5dkRLNi1aYlgwaFBB?oc=5","date":"2021-11-29","type":"pipeline","source":"ASIS","summary":"Overcoming Five Preventive Intelligence Hurdles - ASIS","headline":"Overcoming Five Preventive Intelligence Hurdles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZUVoaUxkbmxGRERFaEg5TTFUeHUzUmpQRTRrcUVEbzhTSkhkTjdDblRibnFwQ2dlRFFaTmhvVnpScEpFcmQwajBzbkxvRmxqT0o4OF9VUTBOX2NtOTEtc3R4ZmJqRWZkRUVhQUp3NWh5YWY5UVFRY05wRDdJYkJTcFVlS01zTlpTbERtVUFpNFpfYjI3YUVqV1lMMUxfRUJTZmNCcXBkZzZvcXZha2ZoVk1Sbw?oc=5","date":"2021-09-01","type":"pipeline","source":"ASIS","summary":"Certification Profile: Pamela Mischo, CPP - ASIS","headline":"Certification Profile: Pamela Mischo, CPP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNX3RkN215RW42b1IzdTdNakZpOWxNNmI2Y1NmVmtqbTN0UlJ3Qkpna19fNzVMX0UtMVY1T3p1M0ZBQXRHSjJ2WVhiZnljU1RXUmRzV2Myd1VybFdtdEtjcTVVR0haUmM2RUZrT0lFdFBwQmQtM0ZpYlFPZ0VpNXdlRXlWY21RTVd4Ym5TT0lXcGNlaEZkMGRjRmpFQlRTUF9rS1F5SUtB?oc=5","date":"2014-10-01","type":"pipeline","source":"ASIS","summary":"In Search of Security Metrics - ASIS","headline":"In Search of Security Metrics","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_1":8},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}